MX2023004729A - Composiciones y metodos de vacunacion contra neisseria gonorrhoeae. - Google Patents

Composiciones y metodos de vacunacion contra neisseria gonorrhoeae.

Info

Publication number
MX2023004729A
MX2023004729A MX2023004729A MX2023004729A MX2023004729A MX 2023004729 A MX2023004729 A MX 2023004729A MX 2023004729 A MX2023004729 A MX 2023004729A MX 2023004729 A MX2023004729 A MX 2023004729A MX 2023004729 A MX2023004729 A MX 2023004729A
Authority
MX
Mexico
Prior art keywords
methods
lipoprotein
compositions
neisseria gonorrhoeae
vaccination against
Prior art date
Application number
MX2023004729A
Other languages
English (en)
Inventor
Gregory Moe
Serena Giuntini
Original Assignee
Omvax Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Omvax Inc filed Critical Omvax Inc
Publication of MX2023004729A publication Critical patent/MX2023004729A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0047—Sonopheresis, i.e. ultrasonically-enhanced transdermal delivery, electroporation of a pharmacologically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/36—Adaptation or attenuation of cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1025—Acyltransferases (2.3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6018—Lipids, e.g. in lipopeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/035—Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/101—Plasmid DNA for bacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y203/00—Acyltransferases (2.3)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La divulgación provee composiciones, y métodos de uso de las mismas, para vacunas para el tratamiento de una infección gonocócica y/o meningocócica, que comprenden vesículas nativas de membrana externa (NOMV) derivadas de bacterias que contienen una proteína gonocócica, que es una lipoproteína o que se modifica para que sea una lipoproteína. También se proveen cepas meningocócicas que contienen un gen que codifica una proteína gonocócica, que es una lipoproteína o que se modifica para que sea una lipoproteína.
MX2023004729A 2020-10-23 2021-10-22 Composiciones y metodos de vacunacion contra neisseria gonorrhoeae. MX2023004729A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063104819P 2020-10-23 2020-10-23
PCT/US2021/056249 WO2022087407A1 (en) 2020-10-23 2021-10-22 Compositions and methods for vaccination against neisseria gonorrhoeae

Publications (1)

Publication Number Publication Date
MX2023004729A true MX2023004729A (es) 2023-06-29

Family

ID=81290088

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023004729A MX2023004729A (es) 2020-10-23 2021-10-22 Composiciones y metodos de vacunacion contra neisseria gonorrhoeae.

Country Status (11)

Country Link
US (1) US20230256072A1 (es)
EP (1) EP4232158A1 (es)
JP (1) JP2023546665A (es)
KR (1) KR20230112625A (es)
CN (1) CN116670157A (es)
AU (1) AU2021364838A1 (es)
CA (1) CA3166272A1 (es)
CL (1) CL2023001142A1 (es)
IL (1) IL302286A (es)
MX (1) MX2023004729A (es)
WO (1) WO2022087407A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117535333B (zh) * 2024-01-04 2024-04-23 南方医科大学皮肤病医院（广东省皮肤病医院、广东省皮肤性病防治中心、中国麻风防治研究中心） 促进淋球菌外膜囊泡分泌的方法、淋球菌敲除株及其制备方法和应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2289545T3 (en) * 2000-01-17 2016-09-05 Glaxosmithkline Biologicals Sa Supplemented OMV vaccine against meningococcus
GB0213622D0 (en) * 2002-06-13 2002-07-24 Glaxosmithkline Biolog Sa Vaccine Corporation
US7357932B2 (en) * 2004-06-16 2008-04-15 Center Of Disease Control Department Of Health Surface protein of Neisseria bacteria
TW201221642A (en) * 2010-11-15 2012-06-01 Nat Health Research Institutes Method of producing lipidated polypeptides

Also Published As

Publication number Publication date
US20230256072A1 (en) 2023-08-17
AU2021364838A9 (en) 2024-05-23
EP4232158A1 (en) 2023-08-30
KR20230112625A (ko) 2023-07-27
WO2022087407A1 (en) 2022-04-28
CL2023001142A1 (es) 2023-12-15
AU2021364838A1 (en) 2023-06-08
IL302286A (en) 2023-06-01
JP2023546665A (ja) 2023-11-07
CN116670157A (zh) 2023-08-29
CA3166272A1 (en) 2022-04-28

Similar Documents

Publication Publication Date Title
NZ598458A (en) Hybrid polypeptides including meningococcal fhbp sequences
RU2014104241A (ru) Способ бездетергентного получения везикул наружной мембраны грамотрицательной бактерии
BR112012022688A2 (pt) proteína de fusão, vesícula da membrana externa isolada, polinucleotídeo, composição farmacêutica, vacina, método para tratamento ou prevenção de infecção ou doença por neisseria, uso e método para fabricar uma proteína de fusão
WO2004014417A3 (en) Vaccine compositions comprising l2 and/or l3 immunotype lipooligosaccharides from lgtb- neisseria minigitidis
MX2009006760A (es) Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedades meningococicas.
MX2011012234A (es) Plasmido libre de antibiotico.
BR0015961A (pt) Antìgeno de neisseria de 85kda
JP2014520801A5 (es)
NZ593674A (en) Meningococcal vaccines including hemoglobin receptor
MX2010002867A (es) Cepas de micoplasma atenuadas vivas.
MX2010002866A (es) Capas de mycoplasma gallisepticum atenuadas.
MX2023004729A (es) Composiciones y metodos de vacunacion contra neisseria gonorrhoeae.
WO2014009971A3 (en) Non-alcoholic vaccine compositions free from animal- origin and process for preparation thereof
TW201026852A (en) Process for production of vaccines
PT1154791E (pt) Composições e métodos de vacinação contra neisseria
WO2023004415A3 (en) Sars-cov-2 vaccine using bacterial spores expressing antigenic fragments
JP2015506691A (ja) 発酵方法
Zhu et al. Commensal Neisseria species share immune suppressive mechanisms with Neisseria gonorrhoeae
EA202190914A1 (ru) Иммуногенные композиции
MX2023009728A (es) Vacuna recombinante meningococica b.
RU2432174C1 (ru) Способ получения эшерихиозного анатоксина
EA202090908A1 (ru) Вакцина и связанные композиции для лечения пародонтита и способ применения
RU2008144180A (ru) Вакцина против микоплазмы и prrsv
MX2023002786A (es) Vesículas de membrana exterior.
US10960067B2 (en) Meningococcal infection and modified Neisseria lactamica